Thus, pancreatic tumor cells lacking Atm expression might undergo an evolutionary process upon long-term exposure to components of the FOLFIRINOX regimen, most likely by selecting for more aggressive subclones. The gene discussed is ATM; the disease is pancreatic neoplasm.